Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Javitt

Showing results (21-30 of 267) with videos related to

Pageof 27
Sort By:
The American Journal of Managed Care|September 3, 2014
Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overviewDaniel C Javitt
Schizophrenia Bulletin|October 17, 2009
Sensory processing in schizophrenia: neither simple nor intactDaniel C Javitt
Novartis Foundation Symposium|May 24, 2008
Phenomenology, aetiology and treatment of schizophreniaDaniel C Javitt
The Lancet. Psychiatry|November 7, 2016
Bitopertin in schizophrenia: glass half full?Daniel C Javitt
Current Treatment Options in Psychiatry|August 25, 2015
Current and emergent treatments for symptoms and neurocognitive impairment in schizophreniaDaniel C Javitt
Handbook of Experimental Pharmacology|October 3, 2012
Glycine transport inhibitors in the treatment of schizophreniaDaniel C Javitt
Advances in Neurobiology|November 19, 2024
Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in SchizophreniaDaniel C Javitt
The American Journal of Psychiatry|January 2, 2015
Sensory processing dysfunction in the personal experience and neuronal machinery of schizophreniaDaniel C Javitt, Robert Freedman
Advances in Neurobiology|November 19, 2024
Advanced Methodology for Neurophysiological Analysis and Biomarker Development: Time-Frequency and Source-Localization ApproachesPejman Sehatpour, Daniel C Javitt
Behavioural Brain Research|May 13, 2009
Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamateStephan Bickel, Daniel C Javitt
Pageof 27

Showing results (21-30 of 267) with videos related to

Sort By:
Pageof 27
The American Journal of Managed Care|September 3, 2014
Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overviewDaniel C Javitt
Schizophrenia Bulletin|October 17, 2009
Sensory processing in schizophrenia: neither simple nor intactDaniel C Javitt
Novartis Foundation Symposium|May 24, 2008
Phenomenology, aetiology and treatment of schizophreniaDaniel C Javitt
The Lancet. Psychiatry|November 7, 2016
Bitopertin in schizophrenia: glass half full?Daniel C Javitt
Current Treatment Options in Psychiatry|August 25, 2015
Current and emergent treatments for symptoms and neurocognitive impairment in schizophreniaDaniel C Javitt
Handbook of Experimental Pharmacology|October 3, 2012
Glycine transport inhibitors in the treatment of schizophreniaDaniel C Javitt
Advances in Neurobiology|November 19, 2024
Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in SchizophreniaDaniel C Javitt
The American Journal of Psychiatry|January 2, 2015
Sensory processing dysfunction in the personal experience and neuronal machinery of schizophreniaDaniel C Javitt, Robert Freedman
Advances in Neurobiology|November 19, 2024
Advanced Methodology for Neurophysiological Analysis and Biomarker Development: Time-Frequency and Source-Localization ApproachesPejman Sehatpour, Daniel C Javitt
Behavioural Brain Research|May 13, 2009
Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamateStephan Bickel, Daniel C Javitt
Pageof 27